A2 Refereed review article in a scientific journal

Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities




AuthorsLuca Antonioli, Gennady G. Yegutkin, Pál Pacher, Corrado Blandizzi, György Haskó

PublisherCell Press

Publication year2016

JournalTrends in Cancer

Volume2

Issue2

First page 95

Last page109

Number of pages15

ISSN2405-8025

eISSN2405-8033

DOIhttps://doi.org/10.1016/j.trecan.2016.01.003


Abstract

Over recent years, significant advances in cancer immunotherapy have been made due to a better understanding of the principles underlying tumor biology and immunology. In this context, ecto-5′-nucleotidase (CD73) is a key molecule, because the degradation of AMP into adenosine results in the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer. Targeting CD73 has resulted in favorable antitumor effects in preclinical models, and the combined treatment of CD73 blockade with other immune-modulating agents [i.e., anti-cytotoxic T lymphocyte antigen (CTLA)-4 monoclonal antibodies (mAb) or anti-programmed cell death protein (PD)-1 mAb] is a particularly attractive therapeutic option. Although there is still a long way to go, anti-CD73 therapy, through the development of CD73 mAb, could constitute a new biologic therapy for treating patients with cancer. In this review, we discuss the link between CD73 and the onset, development, and spread of tumors, highlighting the potential value of this molecule as a drug target and a novel biomarker in the context of personalized cancer therapy.



Last updated on 2024-26-11 at 14:58